AnaptysBio, Inc. (NASDAQ:ANAB) – Research analysts at Jefferies Group issued their FY2017 earnings estimates for shares of AnaptysBio in a research report issued to clients and investors on Thursday. Jefferies Group analyst B. Amin expects that the biotechnology company will earn ($1.65) per share for the year. Jefferies Group currently has a “Buy” rating and a $101.00 target price on the stock. Jefferies Group also issued estimates for AnaptysBio’s Q4 2017 earnings at ($0.40) EPS, Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at ($0.33) EPS, Q3 2018 earnings at ($0.37) EPS, Q4 2018 earnings at ($0.40) EPS, FY2018 earnings at ($1.33) EPS, FY2019 earnings at ($2.54) EPS, FY2020 earnings at ($3.27) EPS and FY2021 earnings at ($5.14) EPS.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.02. ILLEGAL ACTIVITY WARNING: “FY2017 Earnings Forecast for AnaptysBio, Inc. (ANAB) Issued By Jefferies Group” was first posted by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://weekherald.com/2017/11/15/fy2017-earnings-forecast-for-anaptysbio-inc-anab-issued-by-jefferies-group.html.
Several other equities research analysts have also recently commented on the stock. JMP Securities lifted their price target on shares of AnaptysBio from $45.00 to $82.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 10th. Credit Suisse Group lifted their price target on shares of AnaptysBio from $34.00 to $38.00 and gave the stock an “outperform” rating in a research report on Friday, August 25th. Zacks Investment Research cut shares of AnaptysBio from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Wedbush reiterated an “outperform” rating and set a $75.00 price target (up previously from $37.00) on shares of AnaptysBio in a research report on Friday, October 13th. Finally, Royal Bank Of Canada initiated coverage on shares of AnaptysBio in a research report on Thursday, September 14th. They set an “outperform” rating and a $40.00 price target for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $81.00.
Shares of AnaptysBio (NASDAQ ANAB) opened at $71.08 on Monday. AnaptysBio has a 1 year low of $15.17 and a 1 year high of $74.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77.
In related news, major shareholder Holdings A/S Novo sold 356,300 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the completion of the transaction, the insider now owns 1,936,604 shares in the company, valued at $40,862,344.40. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Evercore Wealth Management LLC acquired a new position in AnaptysBio during the third quarter valued at approximately $100,000. Legal & General Group Plc grew its holdings in AnaptysBio by 160.8% during the third quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 1,951 shares during the period. Bank of America Corp DE acquired a new position in AnaptysBio during the first quarter valued at approximately $123,000. DAFNA Capital Management LLC grew its holdings in AnaptysBio by 22.2% during the second quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 1,000 shares during the period. Finally, New York State Common Retirement Fund acquired a new position in AnaptysBio during the second quarter valued at approximately $168,000. Hedge funds and other institutional investors own 59.04% of the company’s stock.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.